From blood-based biomarkers to AI-powered tools, discover how 9 innovations are being tested in the NHS to speed up dementia ...

All NICE products on prostate cancer. Includes any guidance, advice and quality standards.

This guideline has been updated and replaced by epilepsies in children, young people and adults ...

Evidence-based recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-low metastatic or unresectable breast cancer after chemotherapy in adults. This guidance updates and replaces NICE ...

There is a commercial access agreement for dupilumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess@sanofi.com ...

This guide describes the methods and processes, including expected timescales, that NICE follows when producing technology appraisal and highly specialised technologies guidance. The methods and ...

This guidance has been updated and replaced by NICE technology appraisal guidance 736 ...

intermittently scanned continuous glucose monitoring. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following ...

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years Technology appraisal guidance TA554 Published: 21 December 2018 ...

We have moved interventional procedures guidance 666 to become HealthTech guidance 535. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...

This guideline covers nutrition and weight management in pregnancy for anyone who may become pregnant, is planning to become pregnant or is already pregnant, and nutrition in children up to 5 years.

There is a simple discount patient access scheme for faricimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...